10 completed, 10 recruiting, 9 unknown, 6 not yet recruiting. 41 Phase 2, 7 Phase 1, 1 Phase 3.
Follow cryoablation: new trials by email Literature Review of cryoablation trials Research Report on cryoablation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma Anlotinib, TQB2868 Injection, cryoablation - Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Fudan University | 56 | 2026-10-01 | 2026-09-29 |
| Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors PD-1 and chemotherapy, cryoablation - Biliary Tract Cancer (BTC) | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-10-01 | 2026-07-24 |
| Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine - Melanoma (Skin) Stage IV | Phase 2 | Recruiting | Sun Yat-sen University | 28 | 2026-10-01 | 2026-09-29 |
| Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer. QL1706 (Iparomlimab/Tuvonralimab), Lenvatinib, Cryoablation - Biliary Tract Cancer (BTC) | Phase 2 | Not yet recruiting | Fudan University | 180 | 2026-09-20 | 2026-09-21 |
| Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers Cryoablation, Cryoablation combined with PD1 Inhibitor - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Texas Tech University Health Sciences Center | 36 | 2026-03-01 | 2025-09-09 |
| SEED-CRYO: Sequential 125I Seed Implantation Followed by Cryoablation vs Single-Modality Local Therapy in Unresectable Solid Tumors Iodine-125 (125I) Seed Implantation, cryoablation, Sequential 125I Seed Implantation Followed by Cryoablation - Unresectable Solid Tumors | Phase 2 | Not yet recruiting | Li Min | 150 | 2026-02-01 | 2026-03-04 |
| Lesion-Allocated Therapy for Multiple Metastases and Tumor-Zoned Treatment for Bulky Tumors: A Phase II Study of Iodine-125 Seed Implantation Combined With Cryoablation in High-Burden Metastatic Disease Iodine-125 (125I) Seed Implantation (Low-Dose-Rate Brachytherapy), cryoablation, Lesion Allocation and Tumor Zoning Strategy - High-Burden Metastatic Solid Tumors | Phase 2 | Not yet recruiting | Li Min | 90 | 2026-02-01 | 2026-02-27 |
| Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy Cryoablation, Dual-Function Antibody PD-1/CTLA-4 - Pancreatic Adenocarcinoma Locally Advanced | Phase 2 | Recruiting | Ruijin Hospital | 20 | 2025-12-15 | 2025-12-29 |
| Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma. SHR-1701, Famitinib, Cryoablation - Advanced Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Fudan University | 36 | 2025-09-01 | 2025-08-28 |
| Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Lenvatinib, cryoablation - Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Recruiting | Fudan University | 56 | 2025-08-20 | 2025-08-12 |
| Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01) Tislelizumab, Lenvatinib, cryoablation - Intrahepatic Cholangiocellular Carcinoma | Phase 2 | Recruiting | Fudan University | 92 | 2025-03-18 | 2025-04-06 |
| Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma Cryoablation, PD-1 antibody and bevacizumab - Carcinoma, Hepatocellular | Phase 2 | Unknown | Shanghai Zhongshan Hospital | 36 | 2024-07-31 | 2024-07-31 |
| Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC Toripalimab, Cryoablation - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Shanghai Chest Hospital | 54 | 2024-04-02 | 2025-09-05 |
| Cryoablation+Ipilimumab+Nivolumab in Melanoma Ipilimumab, Nivolumab, Cryoablation - Metastatic Melanoma, Skin Cancer | Phase 2 | Recruiting | Massachusetts General Hospital | 37 | 2023-09-23 | 2026-08-27 |
| Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11) Tislelizumab, Lenvatinib, Cryoablation - Solid Tumor, Adult | Phase 2 | Recruiting | Fudan University | 25 | 2023-09-13 | 2025-02-27 |
| Study of Cryoablation and Nirogacestat for Desmoid Tumor Nirogacestat, Cryoablation - Desmoid Tumor | Phase 2 | Recruiting | Nam Bui | 28 | 2023-08-15 | 2026-09-10 |
| Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10) Cryoablation, Tislelizumab, Lenvatinib - Hepatocellular Carcinoma | Phase 2 | Unknown | Fudan University | 25 | 2023-06-20 | 2023-06-27 |
| Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09) Cryoablation, Tislelizumab, Lenvatinib - Gastric Cancer Metastatic to Liver | Phase 2 | Unknown | Fudan University | 25 | 2023-06-16 | 2023-06-27 |
| Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free) Cryoablation, Sintilimab, Lenvatinib - Advanced Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Fudan University | 30 | 2023-04-28 | 2023-05-31 |
| Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08） Sintilimab, Lenvatinib, Cryoablation - Advanced Biliary Tract Cancer | Phase 2 | Unknown | Fudan University | 25 | 2023-03-23 | 2023-03-24 |
Showing 20 of 41. Sign in to see all of them.
Carcinoma, Hepatocellular (6) · Melanoma (6) · Biliary Tract Neoplasms (4) · Cholangiocarcinoma (4) · Breast Neoplasms (3) · Colorectal Neoplasms (3) · Sarcoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Liver Neoplasms (2) · Neoplasm Metastasis (2) · Osteosarcoma (2) · Bile Duct Neoplasms (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Cirrhosis, Familial, with Pulmonary Hypertension (1)
Fudan University (13) · Mirror Biologics, Inc. (3) · Li Min (2) · Massachusetts General Hospital (2) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · Rampart Health, L.L.C. (2) · Sun Yat-sen University (2) · Children's National Research Institute (1) · Kristen Ganjoo (1) · M.D. Anderson Cancer Center (1) · Michael Har-Noy (1) · Nam Bui (1) · Ruijin Hospital (1) · Shanghai Chest Hospital (1)
China (21) · United States (15) · Canada (1) · Israel (1) · Thailand (1)
Peng Wang, MD (5) · Min Li (2) · Peng Wang (2) · Tim F Greten, M.D. (2) · AeRang Kim, MD, PhD (1) · Anil Kapoor, MD (1) · Brian Van Tine, M.D., Ph.D. (1) · David G Bostwick, M.D., M.B.A. (1) · David G Bostwick, M.D.,M.B.A. (1) · Dr. Michael Har-Noy (1) · Eric Wehrenberg-Klee, MD (1) · Jian Zhou (1) · Kristen Ganjoo, MD (1) · Madappa Kundranda, MD PHD (1) · Matthew S. Block, M.D., Ph.D. (1)
PMID 18054441, PMID 18565579, PMID 18834631, PMID 21123824, PMID 22075702, PMID 27816492, PMID 28923358, PMID 29487221, PMID 30578687, PMID 30688989, PMID 38205877, PMID 39965889, PMID 41176543
P50CA097274 (1), R01CA219960 (1)